For the first time, researchers have shown that a class of anti-fibrotic drugs slows the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). Research conducted in part at National Jewish ...
Sep 22, 2022
0
21
An early phase trial of a drug currently used to treat lung fibrosis has shown it may also help patients who suffer from a common form of heart failure.
Aug 13, 2021
0
441
Scientists have zeroed in on a culprit that spurs damaging inflammation in the heart following a heart attack. The guilty party is a type of immune cell that tries to heal the injured heart but instead triggers inflammation ...
Jun 7, 2018
0
90
Johns Hopkins researchers report evidence from mouse studies that a "repurposed" drug that would be expected to improve the immune system response of tuberculosis patients may be increasing resistance to the antibiotic drugs ...
Sep 6, 2016
0
0
(HealthDay)—A pair of drugs offers new hope to patients with a progressive, fatal disease that robs their breath by scarring the lungs, according to clinical trial results.
May 18, 2014
0
0
Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since the beginning of 2011. ...
Jan 3, 2012
0
0
The CAPACITY study, published Online First and in an upcoming Lancet, shows that pirfenidone reduces the rate of decline of lung function in patients with idiopathic pulmonary fibrosis—a condition of unknown cause affecting ...
May 13, 2011
0
0
